Home Featured

Featured

Random

Hallucinating Long After the Trip is Over: HPPD – Part 2

New Jersey Gov Signs Bill Reclassifying Psilocybin

Psychedelic Synesthesia: Smell That Tune

Psychedelics Weekly – Field Trip Health Closes Five Clinics, Legalization Bills Introduced in VT, and Ketamine Telehealth Uncertainty

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Field Trip Health Announces $50 Million Bought Deal Offering of Common...

PT257 – Robin Divine – Black People Trip

Awakn Life Sciences to Commence Trading on the NEO Exchange under...

COMPASS Pathways plc announces financial results and business highlights for the...

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety...

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use...

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with...

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

Psychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics,...

Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI

12 3...243 Page 1 of 243

EDITOR PICKS

PT467 – The Role of Religion, Psychedelic Chaplaincy, and Spiritual Care

Pα+ Library: Bifurcated Scheduling

PT466 – The Philosophy of Alfred North Whitehead: Understanding Reality and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.